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Targeted Treatment Protocol in Patellofemoral Pain (TIPPs): Does Treatment Designed 1 
According to Subgroups Improve Clinical Outcomes in Patients Unresponsive to 2 
Multimodal Treatment? 3 
 4 
Background: Targeted intervention for subgroups is a promising approach for the 5 
management of patellofemoral pain.  6 
Hypothesis:  7 
The hypotheses were that the assessment and subgroup classification is clinically feasible, and 8 
that targeted treatment designed according to the characteristics of three subgroups of PFP 9 
patients would show clinical benefits over and above a multimodal intervention. 10 
Study Design: A prospective crossover intervention. 11 
Level of Evidence: Level III 12 
Methods: PFP patients (n=61, mean age: 27±9 years) were enrolled. PFP patients received 13 
standard multimodal treatment three times a week for 6 weeks. Patients not responding to 14 
multimodal treatment were then classified into one of 3 subgroups “strong”, “weak and tight” 15 
and “weak and pronated foot” using six simple clinical tests. They subsequently were 16 
administered a further 6 weeks of targeted intervention designed according to subgroup 17 
characteristics. Visual Analog Scale (VAS), Perception of Recovery Scale (PRS), EQ-5D-5L, 18 
and S-LANSS were used to assess pain, knee function and quality of life before and after the 19 
interventions.  20 
Results: 36% of the patients (21 patients) demonstrated recovery following multimodal 21 
treatment.  However, over 70% (29 patients) of these non-responders demonstrated recovery 22 
after targeted treatment. The VAS, PRS, S-LANSS, and EQ-5D-5L scores improved 23 
significantly after targeted intervention compared to after multimodal treatment (p<0.001). 24 
The VAS score at rest was significantly lower in the weak and pronated foot, and weak and 25 
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tight subgroups (p=0.011, p=0.008) respectively. Post-treatment pain intensity on activity was 26 
significantly lower in the “strong” subgroup (p=0.006).  27 
Conclusion: Targeted treatment designed according to subgroup characteristics improves 28 
clinical outcomes in patients unresponsive to multimodal treatment.  29 
Clinical Relevance: Targeted intervention could be easily implemented following six simple 30 
clinical assessment tests to subgroup patients into one of three subgroups (strong, weak and 31 
tight, weak and pronated foot). Targeted interventions applied according to the characteristics 32 
of these subgroups have more beneficial treatment effects than a current multimodal treatment 33 
program. 34 
 35 
Key words: Rehabilitation, knee injuries, patella, treatment outcome, pain perception 36 
 37 
INTRODUCTION 38 
Patellofemoral pain (PFP) is a chronic musculoskeletal problem that causes persistent anterior 39 
knee pain.2,3,6,8,14,15,20,21,25,26,32,33,45 Despite its widespread use in clinics, it is difficult to 40 
suggest that the current multimodal treatment approach leads to successful outcomes in the 41 
majority of patients with PFP, as it has been reported that only 46% of patients’ knees were 42 
pain free at discharge.2 This indicates that over half of PFP patients do not respond to 43 
treatment and may continue their lives with chronic anterior knee pain.  44 
Identification of the factors leading to these low treatment success rates has consistently been 45 
made a priority by previous International Patellofemoral Pain Research Retreats.4,10,12,48 The 46 
most important factor affecting the success of treatment that has emerged is that patients have 47 
a variety of musculoskeletal and biomechanical differences. The current multimodal 48 
treatment, therefore, may not affect the heterogeneous PFP patient population with the same 49 
efficiency. The idea of clinically subgrouping PFP patients and delivering targeted treatments 50 
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has been strongly recommended for future investigations from consensus based 51 
recommendations regarding treatment for patellofemoral pain from the International 52 
Patellofemoral Pain Research Retreats .4,12,48 Selfe et al. 39 provide an overview of previously 53 
published PFP subgroups and the methods used to derive subgroups in PFP and identified that 54 
patients with PFP exhibit different anthropometric and biomechanical characteristics and do 55 
not form a homogeneous group. Moreover, the most evidence based method for deriving 56 
subgroups found 3 subgroups in the PFP population, which were characterised as “strong”, 57 
“weak and tight” and “weak and pronated foot”.38 This progress allows for a new targeted 58 
treatment approach for PFP to be explored. However, being able to classify patients into 59 
subgroups has limited clinical importance without further evidence of the efficacy of targeted 60 
interventions applied according to the characteristics of these subgroups. Therefore, the 61 
purpose of this study was to assess the clinical outcomes of targeted treatments designed 62 
according to the characteristics of the three subgroups of PFP patients as described by Selfe et 63 
al.38 The hypotheses were that the assessment and subgroup classification is clinically 64 
feasible, and that targeted treatments designed according to the characteristics of the three 65 
subgroups of PFP patients would show clinical benefits over and above a multimodal 66 
intervention. 67 
 68 
METHOD 69 
Design 70 
A prospective crossover intervention study design was used (Figure 1).  71 
Participants 72 
Patients aged between 18  and 40 attending a physiotherapy outpatient clinic at a University 73 
Hospital with a clinical diagnosis of patellofemoral pain were approached for eligibility in this 74 
study. Eligibility criteria were based on previously defined PFP criteria.7,38,44 Subjects were 75 
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excluded if they had any of the following: previous knee surgery, clinical evidence of 76 
ligamentous instability and/or internal derangement, a history of patellar subluxation or 77 
dislocation, joint effusion, true knee joint locking and/or giving way, bursitis, patellar or 78 
iliotibial tract tendinopathy, Osgood Schlatter’s disease, Sinding-Larsen Johansson Syndrome, 79 
muscle tears or symptomatic knee plicae, serious co-morbidity which would preclude or affect 80 
compliance with the assessment, or were pregnant. 81 
 82 
Subgroup Classification Method 83 
Quadriceps and Hip Abductor muscle strength 31, Patellar glide test42,50, Quadriceps length49, 84 
Gastrocnemius length49, and Foot posture index36 assessments were performed to classify all 85 
consenting patients into one of three subgroups (strong, weak and tight, weak and pronated 86 
foot) using the algorithm derived from the work by Selfe et al.38 87 
 88 
Intervention 89 
Multimodal Treatment 90 
The multimodal treatment program was designed based on the usual exercise and modalities 91 
used in local clinics.20,21,32,45 All patients received standard, supervised, 60 min multimodal 92 
treatment three times a week for 6 weeks. Table 1 shows the details of the multimodal 93 
rehabilitation program. 94 
Targeted Treatment 95 
Patients who did not respond to multimodal treatment were assigned to one of the treatment 96 
groups “strong”, “weak and tight”, and “weak and pronated foot”. They then followed a 97 
further 6 week, 45 min targeted intervention program administered three times a week. The 98 
targeted treatment program was designed according to the key deficits identified in each 99 
patient by the subgrouping clinical assessment tests. The patients in the “strong” subgroup 100 
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had no muscle strength deficit therefore, the intervention program for this subgroup was 101 
targeted at improving neuromuscular control and coordination ability using proprioceptive 102 
exercises such as progressive balance exercises, and knee braces43,44 which have been shown 103 
to offer improvements in movement control in patients with PFP (Selfe et al. 2011), 104 
reductions in patellofemoral reaction forces (Sinclair et al. 2016) and have been shown to 105 
reduce pain at 6 and 12 months during a PFP rehabilitation program (Uboldi et al., 2018). In 106 
the “weak and tight” subgroup, the exercise program consisted of Closed Kinetic Chain 107 
(CKC) muscle strengthening and stretching, and weight management advice, as a larger body 108 
mass index was identified as a potentially relevant clinical feature in this subgroup.38 In the 109 
“weak and pronated foot” subgroup, muscle weakness and abnormal foot alignment were 110 
identified as the key factors. Therefore, the intervention program included CKC strengthening 111 
exercises and foot orthoses.5,24 Table 2 shows the details of each of the specific targeted 112 
intervention programs.   113 
Outcome measures 114 
Pain at rest and during activity was the primary outcome measure of this study measured 115 
using the Visual Analog Scale (VAS) 19. Activity was specified by patients. 116 
 117 
The Perception of Recovery Scale was measured using a 7-point Likert scale ranging from 118 
“completely recovered” to “worse than ever”. Patients were classified as “recovered” if they 119 
rated themselves as “completely recovered” or “strongly recovered”. Patients rating 120 
themselves in one of the other five categories from “slightly recovered” to “worse than ever" 121 
were categorised as “not recovered”.35 122 
The EQ-5D-5L was used as a self-reported generic measure of health and quality of life. 123 
Patients rated their overall health on the day of the interview on a 0–100 hash-marked, 124 
vertical visual analogue scale (EQ-5D-5L-VAS). A higher EQ-5D-5L-VAS score indicating 125 
better health status.22 126 
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Neuropathic Pain was measured using The Self-Administered Leeds Assessment of 127 
Neuropathic Symptoms and Signs (S-LANSS) questionnaire. The S-LANSS comprises a 5-128 
item questionnaire regarding pain symptoms and two items for clinical signs involving self-129 
administered sensory tests for the presence of allodynia and decreased sensation to pinprick. 130 
This was used to discriminate the small number of patients who may have neuropathic knee 131 
pain from those with nociceptive pain (Selfe 2017. Chapter 4: Red Flags and Rare pathologies 132 
in 1. Selfe J, Janssen J, Callaghan M (2017).  Patellofemoral Pain an evidence based 133 
Clinical Guide. Nova Science). The possible scores range from 0 to 24, with a score of 12 or 134 
greater considered to be suggestive of neuropathic pain.28 Finally, a single leg hop test was 135 
used to determine functional performance.1 Distance was measured from toe to heel and the 136 
mean score of three repetitions was recorded.  137 
Data analysis 138 
A sample size calculation was performed based on the minimal detectable change on the pain 139 
VAS. Data from a previous study indicates that the VAS scores in patients with PFP was 4.3 140 
± 1 cm,9 with 30% of the maximum score of the VAS-pain considered to be the detectable 141 
change, the sample size for each treatment subgroup was determined to be 8 patients to 142 
achieve a 90% power at the 0.05 level of significance. Data were not normally distributed 143 
when analysed with the Kolmogorov–Smirnov test (p = ??). Consequently, non-parametric 144 
tests were indicated. In addition, the mean of rank scores, standard errors and Z scores were 145 
reported, along with descriptive statistics to describe the general features of the subjects. All 146 
statistical analysis was conducted using SPSS 21.0.  147 
 148 
RESULTS 149 
Of the 128 patients who were screened, 95 were included in the present study. Of these 61 150 
patients completed the multimodal treatment (Figure 1) (Table 3). Twenty-one patients (36%) 151 
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demonstrated recovery following multimodal treatment (Phase I) and were discharged. 40 152 
Patients (64%) not responding to multimodal treatment were administered a further 6 weeks 153 
of targeted intervention designed according to subgroup characteristics (phase 2).  Twenty-154 
nine (72.5%) patients demonstrated recovery following targeted intervention (phase II) and 11 155 
(27.5%) patients did not respond to either of the treatment approaches (Table 4).  156 
Perceived Recovery Scale (PRS), and pain intensity at rest and during activity (VAS) were 157 
significantly  improved after targeted intervention (p<0.001) (Table 5). S-LANSS, EQ-5D-5L 158 
and EQ5D-5L-VAS scores were significantly improved following targeted intervention 159 
compared to pre-targeted treatment scores (p = 0.001, p<0.001, p = 0.02), respectively (Table 160 
5).  161 
Within the three subgroups, the findings showed that pain perception was significantly 162 
improved after targeted treatment compared to pre-targeted treatment levels in the “strong”, 163 
“weak and tight”, and “weak and pronated foot” subgroups (p= 0.005, p= 0.001, p= 0.004) 164 
respectively.  165 
VAS Pain intensity at rest was also significantly lower after targeted intervention in the “weak 166 
and pronated foot” and “weak and tight” subgroups (p=0.011, p= 0.008) respectively, 167 
however within the “strong” subgroup, no change was seen between pre-treatment and post 168 
treatment (p = 0.245) (Table 6). However, pain intensity during activity was significantly 169 
lower after treatment in the “strong” (p=0.006), the “weak and pronated foot” and “weak and 170 
tight” subgroups; although these reductions were not statistically significant (p=0.059, p= 171 
0.06) respectively (Table 6).  172 
Other measures including quadriceps length test, S-LANSS, EQ5D-5L, and EQ5D-VAS were 173 
significantly improved in the “weak and tight” subgroup. S-LANSS, EQ5D-5L, and patellar 174 
mobility were significantly improved in the “weak and pronated foot” subgroup. In the 175 
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“strong” group only gastrocnemius length was significantly different between pre- and post-176 
targeted treatment (p=0.03). Results for outcome measures are shown in Table 7. 177 
 178 
DISCUSSION [Au: Do not repeat results here.] 179 
This study explored the clinical outcome of multimodal followed by targeted intervention for 180 
three specific subgroups of PFP patients. Findings suggest that 36% of PFP patients did 181 
respond to multimodal treatment, which is lower than that reported by Brown et al.2 (46%). . 182 
The results of our study  suggest that the TIPPs subgroups and the algorithm used to classify 183 
PFP patients as "strong", "weak and tight", "weak and pronated foot" 38  is  valid and 184 
clinically implementable. The findings from this study were in agreement with Drew et al.13 185 
who also reported differential response patterns in outcomes at 12 months in their subgroups. 186 
This suggests that targeted interventions based on subgroups, provides an important 187 
development in the treatment strategy for patients with PFP.4,48 188 
When subgroups were examined separately, the distribution of patients was very similar to 189 
that found by Selfe et al.38 however there were slight differences in number of patients 190 
classified as “weak and pronated foot” and “strong” The reasons for this are unclear but may 191 
suggest different care seeking or life style, eating and exercise behaviours. 192 
The “strong” subgroup demonstrated a poor response to multimodal treatment but a 193 
significant improvement was observed after targeted treatment. This finding is consistent with 194 
Greuel et al.18 and Gallina et al.17 who both reported results confirming that motor control of 195 
the quadriceps is problematic in some PFP patients. One explanation for this is improved 196 
neuromuscular control in patients classified as “strong”. Since these patients already 197 
demonstrated relatively high quadriceps muscle torque, targeted intervention was delivered 198 
focusing on progressive development of motor control on unstable surfaces instead of 199 
conventional muscle strength exercises. Given that quadriceps strength did not change as a 200 
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result of the targeted intervention, these progressive balance exercises and the use of patellar 201 
bracing have been shown to improve motor control and stability (Selfe et al., 2011). In 202 
addition, bracing has been linked to the reduction of patellofemoral forces during activities of 203 
daily living and sporting tasks (Sinclair et al, 2016) and improvements within rehabilitation 204 
protocols (Uboldi et al., 2018). This was reflected in the improvement in the other pain related 205 
parameters, However, since the average pre-treatment VAS pain level at rest in this subgroup 206 
was already low a decrease  from 1.8 to 0.7 has minimal clinical relevance. 207 
Clinically the “weak and tight” subgroup appeared to be the most responsive group to 208 
treatment overall with a relatively even split of 52% responding to multimodal treatment and 209 
all of the remaining patients responding to targeted intervention. This finding was not entirely 210 
unexpected as multimodal treatment routinely includes strengthening and stretching exercises. 211 
However, closer analysis of the outcomes in the "weak and tight" subgroup suggest that 212 
although patients’ perception of recovery improved, the VAS activity pain intensity was not 213 
significantly decreased after targeted treatment in this subgroup. Considering muscle 214 
weakness is the main issue in this subgroup, the probable cause of this unexpected finding is 215 
persistent inability to compensate patellofemoral loads especially during relatively high level 216 
activities of daily life such as ascending/descending stairs even after the targeted treatment. 217 
Targeted intervention consisting of functional strengthening may still be insufficient for high 218 
level  activities of daily living which demand  considerable muscular activity, although it 219 
caused approximately a 30% development in muscle torque and a significant improvement in 220 
perception of recovery in this subgroup.  221 
Findings from the “weak and pronated foot” subgroup suggest that targeted treatment 222 
including, foot orthoses and pain free strengthening exercises was also successful in terms of 223 
perception of recovery and VAS pain on rest. Although the same improvement was not 224 
observed in VAS pain during activity. One explanation for this could be the indirect effect of 225 
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the foot orthoses on the knee as the patients showed no improvement in strength after targeted 226 
treatment. Moreover, optimum correction is very difficult to determine during the intervention 227 
of foot orthoses. It has been reported that special single physiotherapy interventions or 228 
combining interventions for patellar taping, mobilisation or manual therapy have beneficial 229 
effects on pain related functional symptoms in PFP.11,30,34 However, the therapeutic effects of 230 
these applications remain limited because PFP patients exhibit a wide variety of structural 231 
features and biopsychosocial differences. It was confirmed with the present study that the 232 
biomechanical and anthropometric  characteristics of patients were not similar. Foot 233 
pronation, for example, was noticeably high in some patients, while some had  neutral foot 234 
alignment. Similarly, quadriceps muscle strength, which is indicated as a predisposing factor 235 
or a most common symptom in previous studies8,51 has been measured as high in some 236 
patients with the remainder having  considerable muscle weakness. Therefore, specific 237 
applications such as foot orthoses, knee braces, tape, and even exercises may not be required 238 
by every patient. Recently, Selfe et al.38 and Drew et al.13 demonstrated that PFP patients 239 
could be classified into subgroups in multicentre studies. However, corresponding  targeted 240 
treatment packages have yet to be developed. The outcome of the present study indicates that 241 
PFP patients who did not respond to standard multimodal rehabilitation and who were then 242 
treated with targeted intervention designed specifically according to these three subgroups 243 
showed improvement in the majority of symptoms related to pain, knee function and quality 244 
of life.  245 
The functional hop test is often used in clinics to measure functional capability.47 Considering 246 
that there was no increase in quadriceps muscle strength in the “weak and pronated foot”, and 247 
“strong” subgroups, an improvement in the hop test scores was not expected.  Possible 248 
reasons why the hop test score did not improve despite the increase in muscle strength in the 249 
“weak and tight” group can be attributed to the inconsistent hop test performance in PFP 250 
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patients. This confirms previous work that reported single legged hop testing was not a 251 
suitable alternative for strength measurements as the correlation between quadriceps strength 252 
measurement using dynamometry and distance achieved during a hop test was found to be 253 
poor.46 254 
Due to the methodological design of this study, patients had received 6 weeks of multimodal 255 
treatment before 6 weeks of targeted treatment with no intervening washout period. This must 256 
be accepted as a limitation since the possible cumulative effects of the previous treatment 257 
(multimodal) were ignored. Therefore, the observed difference in some parameters could be 258 
the result of regression to the mean. 259 
CONCLUSION 260 
The findings of the study confirm that both the TIPPs assessment and subgroup classification 261 
algorithm are clinically feasible. These findings confirm the findings of others13,18,27,38,41 that 262 
patients with PFP are not a homogeneous group, and have biomechanical and structural 263 
differences. The results provide proof of concept  that targeted interventions based on a 264 
hypothesis driven subgrouping approach confer a significant clinical benefit over and above a 265 
multimodal intervention for PFP patients. 266 
 267 
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Table 1. Multimodal Treatment Program 408 
 409 
 410 
MODALITY APPLICATION TYPE 
Thermotherapy Cold packs /20 min 
Transcutaneous Electrical Neural Stimulation (TENS) Conventional mode-20 min   
50-100Hz, 20-60 pulse/sec 
Therapeutic Ultrasound (US) 1 Watt/cm² - 5 min/ around knee joint 
Hamstring/tensor fascia lata/ iliotibial band stretching  30sn/5 rep 
Isometric quadriceps strengthening 
 
10 rep x 3 set 
Isometric hip adductor strengthening 
 
10 rep x 3 set 
OKC knee extension exercise 3 sets of patients’ 8-10 RM, in painless ROM 
OKC Hip adductor exercise side lying/ 3 sets of patients’ 8-10 RM 
Home based exercise program*  
RM: Repetition Maximum, rep: repetition, ROM: Range of motion, OKC: Open kinetic chain 411 
*Home based exercise program included the same applications except TENS, NMES, US 412 
 413 
 414 
Table 2. Targeted treatment program 415 
 416 
STRONG SUBGROUP 
Progressive balance/proprioception exercises Standing on one leg on wobble board  
3 sets of 1 min exercise each leg  
1-3 sets per session depending on pain  
Progression*: Eyes closed, bouncing ball against wall, bouncing 
ball against wall on an unstable surface 
Patellar bracing** Patient was asked to put on knee brace during ADL  
Activity modification  Activity reduction to fit within envelope of function locally 
determined and negotiated with individual patient 
WEAK AND TIGHT SUBGROUP 
CKC strengthening exercises Plie/lunge/single limb squat  
Pain free ROM  
10 reps per set/ 1-3 sets depending on pain 
Gastrocnemius and Quadriceps Stretching exercises 30 seconds static stretch x 3 reps x 1 per day 
 
Weight management strategies Locally determined and negotiated with individual patient 
WEAK AND PRONATED FOOT SUBGROUP 
CKC strengthening exercises Plie/lunge/single limb squat  
Pain free ROM  
10 reps per set/ 1-3 sets depending on pain 
Foot orthoses Custom made insole supporting medial longitudinal arch of 
foot*** 
Activity modification Improve activity levels locally determined and negotiated with 
individual patient  
 
ADL: Activity of Daily Life CKC: Closed Kinetic Chain 417 
*Progression timing in balance exercise was decided by clinician based on patient pain free achievement  418 
  ** Off the shelf knee support with patellar pad was used (Orthocare© material: 5mm neoprene /SBR /nylon jersey/pk). 419 
Brace size was selected by clinician according to patient comfort and patellar coherence (S/M/L/XL sizes were used) 420 
   *** Custom Made Insoles are tailored individually based on static and dynamic examination of load distribution on foot. 421 
using CAT-CAM free step V.1.3.30 422 
 423 
 424 
 425 
426 
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Table 3 Demographic data of patients who participated in the study 427 
 428 
PATIENTS (N=61)  MEAN SD 
AGE (YEAR) 27                                            9               
HEIGHT (CM) 170 8 
WEIGHT (KG) 65 13 
TIME SINCE SYMPTOMS STARTED 
(MO) 
24                          28 
 BMI (KG/M2) 22.5 3 
 429 
 430 
Table 4. Perception of recovery after treatments 431 
 432 
 
PHASE 1  
MULTIMODAL TREATMENT 
(N=61) 
PHASE 2  
TARGETED TREATMENT 
(N=40) 
PRS Overall % (n) 
Weak and 
Tight 
%  (n) 
Weak and 
Pronated %  
(n) 
Strong 
%  (n) 
Overall 
%  (n) 
Weak and 
Tight 
%  (n) 
Weak  and 
Pronated %  
(n) 
Strong 
%  (n) 
FULLY IMPROVED 11 (7) 16 (4) - 9 (2) 7.5 (3) 8 (1) - 11( 2) 
GREAT 
IMPROVEMENT 23 (14) 36 (9) 29 (4) 9 (2) 65 (26) 92 (11) 80 (8) 39 (7) 
SOME 
IMPROVEMENT 48 (29) 36 (9) 57 (8) 55(12) 17.5 (7) - 20 (2) 28 (5) 
NO CHANGE 16 (10) 12 (3) 14 (2) 18 (4) 10 (4) - - 22 (4) 
A LITTLE WORSE 4   (3) - - 9 (2) 0 (0) - - - 
 433 
 434 
 435 
 436 
 437 
 438 
 439 
 440 
 441 
 442 
 443 
 444 
 445 
 446 
 447 
 448 
 449 
 450 
 451 
 452 
 453 
 454 
 455 
 456 
 457 
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Table 5. Outcome measures differences in targeted treatment 458 
 459 
*p<0.05, VAS: Visual Analog Scale, S-LANSS: The Leeds Assessment of Neuropathic Symptoms and Signs, EQ5DL: 460 
European Quality 5 Dimension, °: degree 461 
 462 
 463 
 464 
 465 
 466 
 467 
 468 
 469 
 470 
 471 
 472 
 473 
 474 
 475 
 
 
 
 
Before Targeted 
Treatment 
 
After Targeted      
Treatment 
 
 
Outcome Measures (n=40) 
 
Median 
 
Min-Max 
 
Median 
 
Min-Max 
 
Z 
 
p 
Perception of recovery 3 3 - 5 2 1 - 4 -5,034 <0.001* 
VAS activity (cm) 4.4 0.1 - 8.8 1.8 0 - 7.5 -4.075 <0.001* 
VAS rest (cm) 1.7 0 - 7.4 0.5 0 - 7.0 -3.599 <0.001* 
S-LANSS 5 0 - 16 0 0 - 24 -3.449 0.001* 
EQ5D-5L 7 5 - 10 6 5 - 11 -3.704 <0.001* 
EQ5D-VAS 80 30 - 95 85 50 - 100 -2.322 0.020* 
Quadriceps muscle strength 
(Nm/kg) 1,1 0,5- 2,1 1,2 0,6 – 2,3 -3.644 <0.001* 
Hip abductor muscle strength 
(Nm/kg) 1,3 0.7 – 2,6 1,3 0,6 – 1,9 -1.456 0.145 
Patellar mobility test (mm) 12 7 - 25 11 2 - 18 -2.062 0.039* 
Foot posture index 6 0 - 11 6 0 - 12 -0.372 0.710 
Quadriceps length (0) 142.7 115 - 156 145.2 128 - 155 -2.150 0.032 
Gastrocnemius length (0) 19.6 8 - 40 20.5 12.3 - 40 -1.358 0.174 
Jump (cm) 90.2 30 - 180 91 38 - 179 -1.472 0.141 
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Table 6. Differences in subgroups before and after targeted treatment (n=40) 476 
 477 
 BEFORE TREATMENT AFTER TREATMENT Z P 
 Median Min-Max Median Min-Max   
VAS IN 
ACTIVITY  
Weak and 
Pronated (n=10) 
5.3 0.5 – 8.8 2.7 0.2 – 6.6 -1.886 
 
0.059 
Weak and Tight 
Group (n=12) 
3.7 0.4 – 7.7 3 0 – 6.5 -1.883 
 
0.060 
Strong Group 
(n=18) 
5.0 0.1- 8.2 2.0 0 – 7.5 -2.741 0.006* 
VAS AT  REST Weak and 
Pronated (n=10) 
3.9 0 – 7.1 0.8 0 – 3.4 -2.547 
 
0.011* 
Weak and Tight 
Group (n=12) 
1.0 0- 3.5 0.68 0 – 1.6 -2.667 
 
0.008* 
Strong Group 
(n=18) 
1.8 0 – 7.4 0.7 0 – 7 -1.161 
 
0.245 
PRS  Weak and 
Pronated (n=10) 
3 3-4 2 2-3 -2.887 
 
0.004* 
 
Weak and Tight 
Group 
(n=12) 
3 3-4 2 1-2 -3.213 
 
0.001* 
 
Strong Group 
(n=18) 
3 3-5 2.5 1-4 -2.830 
 
0.005* 
 
*p<0.05, VAS: Visual Analog Scale, PRS: Perception of Recovery Scale  478 
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Table 7. Outcome measures in subgroups before and after targeted treatment 
 
*p<0.05, VAS: Visual Analog Scale, LANSS: The Leeds Assessment of Neuropathic Symptoms and Signs, EQ5DL: European Quality 5 Dimension, °: degree
 Weak and Tight subgroup (n=12) Weak and Pronated subgroup (n=10) Strong subgroup (n=18) 
 
Before 
Median (Min-
Max) 
After 
Median (Min-
Max) 
 
Z 
 
p 
Before 
Median (Min-
Max) 
After 
Median (Min-
Max) 
 
Z 
 
p 
Before 
Median (Min-
Max) 
After 
Median (Min-Max) 
 
Z 
 
p 
S-LANSS 5 (0- 11) 0 (0 – 6) -2.716 0.007* 6 (0-11) 0 (0 – 10) -2.410 0.016* 5 (0- 169) 1.5 (0 – 24) -0.947 0.344 
EQ5D-5L 7.5  (5-10) 6 (5– 9) -2.556 0.011* 9 ( 6- 9) 6 (5– 11) -2.203 0.028* 6 (5-10) 6 (5– 10) -1.613 0.107 
EQ5D-VAS 80 (50- 90) 90 (50-95) -2.034 0.042* 80  (50- 90) 80  (50-100) -1.027 0.305 82.5  (30- 95) 82.5  (55-100) -1.444 0.149 
Quadriceps muscle 
strength (Nm/kg) 0.84 (0.5-.1.3) 1.05 (0.6 – 1.4) -3.061 0.002* 1.06 (0,6-2.1) 1.3 (0.7 – 1.6) -1.887 0.059 1.2 (0.9 – 1.6) 1.2 (0.9 – 2.2) -0,893 0.372 
Hip abductor muscle 
strength (Nm/kg) 0.9 (0.7 – 1.4) 1.1  (0.6 –1.6) -1,844 0.065 1.1 (0.7– 1.6) 1.2 (0.9– 1.6) -0.593 0.553 1.4 (0.9– 2.6) 1.5 (1 –1.9) -0.259 0.796 
Patellar mobility test 
(mm) 10 (7- 15) 10 (8- 15) -0.103 0,918 15 (11- 22) 12 (2- 18) -2.325 0.020* 12 (8- 25) 11 (7- 17) -0.803 0,422 
Foot posture index 5 (0-9) 5.5 (2-10) -1.725 0.084 7.5 (4-11) 7.5 (2-12) -0.679 0.497 5 (0-11) 6 (0-12) -0.178 0.859 
Quadriceps length 
(0) 137 (115 – 149) 140 (128 -152) -2.134 0.033* 140 (118 – 152) 146 (130 -155) -1.481 0.139 147 (117 – 155) 148 (128 -155) -0.071 0.943 
Gastrocnemius 
length (0) 18.2 (10-26) 17.4 (12.6-27) -1.295 0.195 21.3 (10-40) 17.3 (12.6-34) -1.244 0.214 19.6 (8-27) 21.5 (12.3-40) -2.120 0.034* 
Jump test (cm) 79.1 (30-115) 81 (38-115) -1.718 0.286 85.4 (40-149) 84.2 (65-154) -1.718 0.086 104.5 (49.3-180.6) 107.2 (57.3-179.3) -0.305 0.760 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
